Sectors
SAVA
Cassava Sciences, Inc.
1.32
2 x 2.34
2 x 2.41
bid
ask
+
0.00
0.00%
12:35 PM
| Ytd | -33.33% | |
| 1y | -25.42% |
1.27
day range
1.34
2.23
52 week range
42.20
| Open | 1.30 | Prev Close | 1.32 | Low | 1.27 | High | 1.34 | Mkt Cap | 115.95M |
| Vol | 134.26K | Avg Vol | 5.19M | EPS | -1.38 | P/E | N/A | Forward P/E | -1.36 |
| Beta | -0.58 | Short Ratio | 1.95 | Inst. Own | 29.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 12-13 | Earning | 05-07 | 50-d Avg | 17.99 | 200-d Avg | 21.09 | 1yr Est | 116.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -1.37 | -0.58 | 0.79 | 57.66% |
| 2024-08-08 | 2024-06 | -0.44 | -1.28 | -0.84 | -190.91% |
| 2024-05-10 | 2024-03 | -0.51 | -1.41 | -0.9 | -176.47% |
| 2024-02-28 | 2023-12 | -0.4 | -0.5 | -0.1 | -25.00% |
| 2023-11-07 | 2023-09 | -0.9 | -0.61 | 0.29 | 32.22% |
| 2023-08-03 | 2023-06 | -0.58 | -0.63 | -0.05 | -8.62% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-26 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2024-11-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-10-08 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| 2024-08-13 | HC Wainwright & Co. | Upgrade | Neutral | |
| 2024-08-08 | Rodman & Renshaw | Upgrade | Buy | Buy |
| 2024-07-19 | HC Wainwright & Co. | Upgrade | Neutral |
Profile
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-05-23 | BARBIER REMI | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
| 2024-04-22 | BARRY RICHARD J | Director | 0.00 | Conversion of Exercise of derivative security |
| 2023-04-30 | GUSSIN ROBERT Z | Director | 10.62K | Conversion of Exercise of derivative security |
| 2024-11-28 | KUPIEC JAMES WILLIAM | Officer | 0.00 | Sale |
| 2023-03-06 | O DONNELL MICHAEL J | Director | 6.87K | Conversion of Exercise of derivative security |
| 2024-05-15 | ROBERTSON SANFORD R | Director | 1.14M | Stock Gift |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 3.26M | 7.86M | 6.78% |
| 2024-09-29 | Vanguard Group Inc | 2.52M | 6.08M | 5.24% |
| 2024-09-29 | State Street Corporation | 1.16M | 2.80M | 2.42% |
| 2024-09-29 | Geode Capital Management, LLC | 1.01M | 2.43M | 2.10% |
| 2024-09-29 | Gallacher Capital Management LLC | 580.04K | 1.40M | 1.21% |
| 2024-09-29 | Morgan Stanley | 519.54K | 1.25M | 1.08% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 1.28M | 3.08M | 2.65% |
| 2024-10-30 | iShares Russell 2000 ETF | 1.05M | 2.52M | 2.17% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 678.63K | 1.64M | 1.41% |
| 2024-08-30 | Fidelity Small Cap Index Fund | 415.51K | 1.00M | 0.86% |
| 2024-10-30 | iShares Russell 2000 Growth ETF | 362.96K | 874.73K | 0.75% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 251.56K | 606.26K | 0.52% |
Dividend
| Dividend | Date |
|---|---|
| 0.75 | 2012-12-13 |
| 2 | 2010-12-13 |
Split
| Split | Date |
|---|---|
| 1 : 7 | 2017-05-10 |